Solventum SOLV - オプションチェーン | ADVFN

US Dollar vs Yen

登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

登録

ホーム
投資
株式
アメリカ
NYSE
Solventum Corporation (SOLV)
Solventum Corporation (SOLV) オプション

Solventum Corporation (SOLV)

66.83

0.03

(0.04%)

終了 12月22日 6:00AM

66.83

0.00

(0.00%)

取引時間後: 9:09AM

SOLV ライブオプションフロー

オプションコール

行使価格	買値	売値	前回の価格	中間価格	前日比	前日比 %	出来高	建玉	最終取引
35.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
40.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
45.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
50.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
55.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
60.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
65.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
70.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
75.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
80.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
85.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
90.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
95.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
100.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

オプションプット

行使価格	買値	売値	前回の価格	中間価格	前日比	前日比 %	出来高	建玉	最終取引
35.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
40.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
45.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
50.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
55.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
60.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
65.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
70.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
75.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
80.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
85.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
90.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
95.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
100.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
MYSZMy Size Inc	US$ 4.2001 (211.12%)	121.03M
NVNINVNI Group Ltd	US$ 8.26 (209.36%)	78.06M
TPICTPI Composites Inc	US$ 2.45 (100.82%)	34M
ICGIntchains Group Ltd	US$ 8.77 (88.60%)	527.94k
HSDTHelius Medical Technologies Inc	US$ 0.884851 (84.34%)	121.95M
CYNCYNGN Inc	US$ 0.4603 (-71.41%)	27.91M
MTEMMolecular Templates Inc	US$ 0.1502 (-57.09%)	8.75M
PRFXPainReform Ltd	US$ 5.15 (-53.85%)	2.94M
GALTGalectin Therapeutics Inc	US$ 1.03 (-48.50%)	9.27M
BCABBioAtla Inc	US$ 0.6923 (-41.82%)	6.25M
EDBLEdible Garden AG Inc	US$ 0.24 (65.06%)	354.33M
NVDANVIDIA Corporation	US$ 134.70 (3.08%)	310.19M
APTOAptose Biosciences Inc	US$ 0.28 (64.51%)	306.25M
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.606999 (6.49%)	293.22M
PLTRPalantir Technologies Inc	US$ 80.55 (8.54%)	281.23M

DewDiligence

DewDiligence 1月前

SOLV 3Q24 Results by Business Segment
%Corp YoY Growth
Segment Sales Organic Sales†
Medical/surgical* 57% +1%
Dental 15% -4%
Health-info systems 16% +2%
Purification/filtration 11% 0% †Excludes acquisitions, divestitures, and currency.

*Includes components for other companies’ medical devices.

DewDiligence

DewDiligence 1月前

SOLV reports 3Q24 results—raises 2024 guidance…

New 2024 guidance is as follows:

• Non-GAAP EPS of $6.50-6.65 (vs prior guidance of $6.30-6.50).

• Organic sales growth of 0.5-1.0% (vs prior guidance of 0-1%).

• FCF of $750-850M (vs prior guidance of $700-800M).

At the current share price (~$77 as I’m typing), the midpoint of the new 2024 non-GAAP EPS guidance range represents a P/E ratio of 11.7x.

PR:
https://investors.solventum.com/image/2024-11-07-Solventum-Reports-Third-Quarter-2024-Financial-Results-and-Raises-Full-Year-Guidance.pdf

CC slides:
https://investors.solventum.com/image/SOLV+Q3+2024+Earnings+Presentation.pdf

DewDiligence

DewDiligence 2月前

SOLV seeking buyer for filtration business, according to WSJ sources:

https://www.wsj.com/business/deals/recent-3m-spinoff-explores-sale-of-filtration-unit-f331a83d

In 2Q24, the filtration segment comprised 12% of SOLV’s sales, but the growth rate was non-existent (#msg-174889792).

DewDiligence

DewDiligence 2月前

SOLV hires CMO:

https://finance.yahoo.com/news/solventum-names-surgeon-diagnostics-pioneer-130000072.html

DewDiligence

DewDiligence 4月前

SOLV 2Q24 CC slides:

https://investors.solventum.com/image/Q2+2024+Earnings+Presentation+-+FINAL+8.8.24.pdf

DewDiligence

DewDiligence 4月前

SOLV 2Q24 Results by Business Segment
%Corp YoY Growth
Segment Sales Organic Sales†
Medical/surgical* 56% +2%
Dental 16% -2%
Health-info systems 16% +4%
Purification/filtration 12% -1% †Excludes acquisitions, divestitures, and currency.

*Includes components for other companies’ medical devices.

DewDiligence

DewDiligence 4月前

SOLV’s raised 2024 guidance is as follows:

https://finance.yahoo.com/news/solventum-reports-second-quarter-2024-200500242.html

• 2024 organic sales growth of 0-1% (up from the prior range of -2% to 0%).

• 2024 non-GAAP EPS of $6.30-6.50 (up from the prior range of $6.10-6.40).

At the current share price ($60.00 as I’m typing), the midpoint of the new 2024 non-GAAP EPS guidance range represents a P/E ratio of 9.4x.

abrooklyn

abrooklyn 4月前

Solventum Reports Second Quarter 2024 Financial Results and Raises Full-Year Guidance

Source: PR Newswire (US)
Separation activities and business continuity on track
Reported sales increased 0.2% to $2.081 billion; organic sales increased 1.3%
GAAP Earnings Per Share (EPS) of $0.51; adjusted EPS1 of $1.56
Generated $355 million in cash from operations; free cash flow1 of $297 million
Raises full-year 2024 organic sales growth and adjusted EPS guidance
ST. PAUL, Minn., Aug. 8, 2024 /PRNewswire/ -- Solventum (NYSE: SOLV) today reported financial results as a stand-alone company for the second quarter ended June 30, 2024.

Solventum Logo (PRNewsfoto/3M Healthcare US Opco LLC)

"As we continue to execute a complex transformation, we're encouraged by our first financial results as an independent company and early ability to maintain business continuity," said?Bryan Hanson, chief executive officer, Solventum. "We are starting from a solid foundation and remain focused on addressing historical underperformance and spin-related topics to unlock significant value creation over time."

DewDiligence

DewDiligence 5月前

Activist_investor_builds_stake_in SOLV—(3M’s healthcare spinoff):

https://finance.yahoo.com/news/peltz-trian-building-stake-3m-230900848.html

DewDiligence

DewDiligence 6月前

SOLV 1Q24 Results by Business Segment
%Corp YoY Growth
Segment Sales (const currency)
Medical/surgical* 56% flat
Dental 17% flat
Health-info systems 16% flat
Purification/filtration 12% +7% *Includes components for other companies’ medical devices.

DewDiligence

DewDiligence 6月前

SOLV’s “AI play”—>heath-information systems segment:

https://finance.yahoo.com/news/solventum-introduces-denials-prevention-solution-130000721.html

Heath-information systems comprised 16% of SOLV’s overall (pro forma) sales in 1Q24 (#msg-174387294), but SOLV expects this figure to steadily increase due to the application of AI.

KingOfSwing...Trading

KingOfSwing...Trading 7月前

Thank for the excellent post. Very useful.

DewDiligence

DewDiligence 7月前

SOLV reports pro forma 1Q24 results—reiterates 2024 guidance:

https://finance.yahoo.com/news/solventum-reports-first-quarter-2024-105000516.html

SOLV was spun out of 3M on 4/1/24, so the 1Q24 financial results are pro forma based on what SOLV would have reported if it had it been an independent company.

SOLV re-iterated 2024 guidance given on 3/19/24—see #msg-174067513. (2024 guidance includes the pro forma financials for 1Q24 and actual SOLV results for the remainder of the year.)

The only consequential update is that SOLV is not initiating a dividend, so that free cash flow can be directed toward paying down debt. This decision is not surprising in light of the large debt load SOLV took on as part of the spinoff from 3M.

p.s. No 1Q24 CC due to the Investor Day webcast just a few weeks ago.

Porgie Tirebiter

Porgie Tirebiter 9月前

All of a sudden, I own shares of SOLV! I guess I should have been paying more attention to 3M.

I've had 3M for years and years, just collecting the dividend and probably not paying enough attention to it!

DewDiligence

DewDiligence 9月前

SOLV begins trading on NYSE following completion of spinoff from 3M:

https://finance.yahoo.com/news/solventum-begins-trading-york-stock-103000676.html

DewDiligence

DewDiligence 9月前

SOLV Investor Day CC slides:

https://d1io3yog0oux5.cloudfront.net/_7984eceea22d0dd69e55aae6e648ee7c/3m/db/3194/30840/presentation/Solventum+Investor+Day+3.19.2024.pdf

DewDiligence

DewDiligence 9月前

SOLV issues 2024 guidance:

https://finance.yahoo.com/news/solventum-hosts-inaugural-investor-day-103000871.html

• Organic revenue growth of -2% to 0%

• Adjusted earnings per share (EPS) of $6.10 to $6.40

• Free cash flow of $700M to $800M

DewDiligence

DewDiligence 9月前

Details of 3M’s SOLV spinoff finalized:

https://finance.yahoo.com/news/3m-board-directors-approves-spin-165500127.html

3M shareholders of record on 3/18/24 will receive 1 share of SOLV for every 4 shares of 3M. The SOLV shares will be distributed before the market open on 4/1/24.

This is a tax-exempt distribution for US residents.

DewDiligence

DewDiligence 10月前

SOLV sells $6.9B of debt in six tranches:

• $1B of 3yr notes @5.45%

• $1.5B of 5yr notes @5.40%

• $1B of 7yr notes @5.45%

• $1.65B of 10yr notes @5.60%

• $1.25B of 30yr notes @5.90%

• $0.5B of 40yr notes @6.00%

The total debt issuance was supposed to $8.4B (according to 3M's recent webcast), but I don't know where the other $1.5B is coming from.

All but $600M of the proceeds will be paid to 3M as consideration for the spin-off of 3M’s healthcare business to SOLV.

DewDiligence

DewDiligence 10月前

SOLV is holding an Investor Day webcast 3/19/24 at 9am ET.

DewDiligence

DewDiligence 10月前

These are the five focal areas for 3M’s healthcare business that will become part of Solventum; they comprise about 25% of 3M’s current company-wide sales:

https://engage.3m.com/purification

https://www.3m.com/3M/en_US/health-information-systems-us/

https://www.3m.com/3M/en_US/medical-us/ (surgical supplies and wound care)

https://www.3m.com/3M/en_US/medical-device-components-us/ (components for other companies’ medical devices)

https://www.3m.com/3M/en_US/oral-care-us/ (dentistry and othodontics)

DewDiligence

DewDiligence 10月前

Further details of 3M/SOLV capitalization:

SOLV will sell $8.4B of new debt, keeping $600M of the proceeds and paying $7.7B as a one-time (tax-free) dividend to 3M. (~$100M of the debt proceeds will go to underwriting fees.)

After the debt issuance and one-time payment to 3M, SOLV will have a debt/EBITDA ratio of ~3.5.

DewDiligence

DewDiligence 10月前

3M sets 4/1/24 date for Solventum spin-off:

https://d1io3yog0oux5.cloudfront.net/_28c5051c41e86ce7771a2dfe11a5ee94/3m/news/2024-02-21_3M_Announces_Filing_of_Form_10_Registration_1826.pdf

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約